Quarterly ResultMay 7, 2026, 04:13 PM
LeonaBio Q1 Net Loss $32.9M; Advances Lasofoxifene Phase 3
AI Summary
LeonaBio reported a net loss of $32.9 million for the first quarter of 2026, an increase from $9.1 million in the prior year, with cash, cash equivalents and investments at $67.7 million. The company is advancing its lead drug candidates, expecting to complete enrollment for the Lasofoxifene Phase 3 ELAINE-3 trial in 4Q 2026 with topline data in 2H 2027, and to initiate a Phase 2 study for ATH-1105 in ALS in 2H 2026. Additionally, LeonaBio announced three new appointments to its Board of Directors.
Key Highlights
- Net loss was $32.9 million for Q1 2026, compared to $9.1 million for Q1 2025.
- Cash, cash equivalents and investments totaled $67.7 million as of March 31, 2026.
- Research and Development expenses increased to $10.3 million in Q1 2026 from $4.3 million in Q1 2025.
- Enrollment for the Lasofoxifene Phase 3 ELAINE-3 clinical trial is expected to complete in 4Q 2026.
- Topline data for the Lasofoxifene Phase 3 trial is anticipated in 2H 2027.
- Phase 2 proof-of-concept study of ATH-1105 in ALS patients is on track to initiate in 2H 2026.
- Fred Callori, Natalie Holles, and Peter B. Silverman were appointed to the Board of Directors.
- Net cash used in operations was $20.9 million for the quarter ended March 31, 2026.